Therapeutics Company Eligible For Up to $330 Million on Successful Achievement of Prespecified Regulatory
Therapeutics Company Eligible For Up to $330 Million on Successful Achievement of Prespecified Regulatory
$ADXN - Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration.
Disclaimer: The information presented in this article is intended for informational purposes only and should not be construed as professional medical advice or an endorsement of any specific treatments or therapies. Readers should consult healthcare professionals for advice related to their medical conditions.
We are working endlessly to provide free insights on the stock market every day, and greatly appreciate those who are paid members supporting the development of the Stock Region mobile application. Stock Region offers daily stock and option signals, watchlists, earnings reports, technical and fundamental analysis reports, virtual meetings, learning opportunities, analyst upgrades and downgrades, catalyst reports, in-person events, and access to our private network of investors for paid members as an addition to being an early investor in Stock Region. We recommend all readers to urgently activate their membership before reaching full member capacity (500) to be eligible for the upcoming revenue distribution program. Memberships now available at https://stockregion.net
Collaborations between companies are pivotal in driving scientific advancements and addressing unmet medical needs. A recent development in this field is the collaboration between Addex Therapeutics and Indivior PLC, focusing on the selection of clinical candidates from their gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) research. This partnership is noteworthy not only for its scientific implications but also for its potential impact on treating substance use disorders and chronic cough.
The Science Behind GABAB Positive Allosteric Modulators
At the core of this collaboration lies the innovative approach of using GABAB positive allosteric modulators. GABAB receptors are part of the Family C class of G-protein coupled receptors (GPCRs), which play significant roles in the central nervous system. These receptors are activated by the neurotransmitter gamma-aminobutyric acid (GABA), which is crucial for maintaining balance in neuronal excitability.
Traditional GABAB receptor agonists, like baclofen, have demonstrated efficacy in treating conditions such as spasticity and alcohol use disorder. However, their broader application is hindered by side effects, rapid clearance, and the development of tolerance. Positive allosteric modulators, in contrast, offer a promising alternative. They enhance the receptor's response to GABA, rather than directly activating the receptor. This approach respects the physiological cycle of receptor activation, potentially reducing side effects and tolerance issues associated with direct agonists. Addex Therapeutics, a clinical-stage biopharmaceutical company, has dedicated years to developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Its lead drug candidate, dipraglurant, is being evaluated for possible use in brain injury recovery, including post-stroke and traumatic brain injury.
Indivior PLC, on the other hand, specializes in developing therapies for substance use disorders. The collaboration with Addex represents an opportunity to leverage both companies’ strengths in allosteric modulator technology and addiction science. The partnership between Addex and Indivior has culminated in the selection of clinical candidates from their joint research efforts on GABAB PAMs. Indivior has identified a compound for further development in treating substance use disorders, marking a significant step in addressing one of the most pressing challenges in healthcare. This selection process was not trivial; it involved extensive research and the application of Addex’s industrial-scale allosteric modulator discovery platform, revealing the depth of collaboration between the two entities.
For Addex, this collaboration also allowed the company to select its compound to advance its independent GABAB PAM program, targeting chronic cough. This decision aligns with Addex’s broader strategy of developing treatments for neurological and respiratory conditions.
Potential Impact on Substance Use Disorder Treatment
Substance use disorders remain a public health challenge worldwide. The development of new therapies that target these disorders is crucial for providing patients with more effective and less burdensome treatment options. By focusing on GABAB PAMs, Indivior and Addex are exploring a novel therapeutic avenue that could offer a new mechanism of action compared to existing treatments.
GABAB receptor modulation could potentially improve outcomes for individuals with substance use disorders by enhancing the effects of naturally occurring neurotransmitters, thereby reducing cravings and withdrawal symptoms. This approach also promises fewer side effects, a advantage over current treatments that often come with a range of adverse effects. Chronic cough, a condition that affects the quality of life, represents another therapeutic area that could benefit from this collaboration. The pathophysiology of chronic cough involves complex neurological mechanisms, and current treatments are often inadequate. Addex’s focus on developing a GABAB PAM for chronic cough could provide a new therapeutic option for patients, potentially offering relief where other treatments have failed.
The collaboration between Addex and Indivior illustrates a broader trend within the pharmaceutical industry: the move towards partnerships that combine expertise across different domains to accelerate drug development. This model of collaboration not only enhances the speed and efficiency of bringing new therapies to market but also increases the chances of scientific breakthroughs. The focus on allosteric modulators highlights an innovative approach in drug development, one that could redefine how certain neurological and psychiatric conditions are treated. As more is understood about the role of these modulators in disease pathways, the potential for developing targeted therapies increases, offering hope to patients with conditions that have been difficult to treat with traditional methods.
The collaboration between Addex Therapeutics and Indivior PLC represents a significant step forward in the development of treatments for substance use disorders and chronic cough. Through their combined efforts, the companies are at the forefront of exploring the potential of GABAB positive allosteric modulators, an approach that could transform the therapeutic landscape for these conditions. As research continues and these clinical candidates advance through development stages, the potential benefits of this collaboration may become more apparent, offering new hope to patients and contributing to the advancement of medical science.
Disclaimer: The information provided in this article is for informational purposes only and should not be considered medical advice. Readers are encouraged to consult healthcare professionals for guidance related to their health conditions and treatment options.
We are working endlessly to provide free insights on the stock market every day, and greatly appreciate those who are paid members supporting the development of the Stock Region mobile application. Stock Region offers daily stock and option signals, watchlists, earnings reports, technical and fundamental analysis reports, virtual meetings, learning opportunities, analyst upgrades and downgrades, catalyst reports, in-person events, and access to our private network of investors for paid members as an addition to being an early investor in Stock Region. We recommend all readers to urgently activate their membership before reaching full member capacity (500) to be eligible for the upcoming revenue distribution program. Memberships now available at https://stockregion.net